Welcome to our dedicated page for T2 Biosystems news (Ticker: TTOO), a resource for investors and traders seeking the latest updates and insights on T2 Biosystems stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect T2 Biosystems's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of T2 Biosystems's position in the market.
T2 Biosystems, Inc. (NASDAQ:TTOO) will report its second-quarter 2021 financial results after market close on August 5, 2021. Following the earnings release, management will host a conference call at 4:30 p.m. ET. The event can be accessed via a live and archived webcast at their website. T2 Biosystems specializes in rapid detection of sepsis-causing pathogens and offers several diagnostic products powered by T2 Magnetic Resonance technology, aiming to enhance patient care while reducing costs.
T2 Biosystems (NASDAQ:TTOO) announced on July 19, 2021, the issuance of inducement awards to eleven new employees under its Inducement Award Plan. The awards include options to purchase 321,000 shares with an exercise price of $1.06, the closing price on July 8, 2021. Options vest over four years, with 25% vesting after one year. This initiative aims to attract talent while complying with Nasdaq rules, supporting T2’s mission in rapid pathogen detection.
T2 Biosystems (NASDAQ:TTOO) is set to participate in three upcoming virtual conferences focusing on rapid diagnostic technology for bloodstream infections and sepsis. The conferences include the World Microbe Forum from June 20-24, the Sepsis Tech and Innovation 2021 on June 23, and the 31st European Congress of Clinical Microbiology & Infectious Diseases on July 12. CEO John Sperzel highlighted the significance of addressing sepsis, which accounts for nearly 20% of global deaths, emphasizing that their products, such as the T2Candida® and T2Bacteria® panels, offer rapid results crucial for effective management.
T2 Biosystems (NASDAQ:TTOO) announced its 2021 Annual Meeting of Stockholders scheduled for June 25, 2021. The Board of Directors fully supports all proposals on the proxy and urges stockholders to participate. CEO John Sperzel emphasized the significance of these proposals in a video message available on the company's Investor Relations site. Stockholders of record as of April 28, 2021, are eligible to vote. Proxy materials and additional shareholder information can be accessed through the SEC's website.
T2 Biosystems (TTOO) reported strong financial results for Q1 2021, with total revenue rising 173% to $7.0 million, including product revenue surging 345% to $4.7 million. Sepsis test utilization in the U.S. increased by 85%, resulting in an annualized test run rate of approximately $111,000 per instrument. The company sold 4 T2Dx instruments, expanded its salesforce to 9 Regional Account Managers, and modified existing contracts to enhance product development. Despite a net loss of $(10.7) million, T2 holds $43.9 million in cash and expects full-year revenues between $24 million and $26 million.
T2 Biosystems (NASDAQ:TTOO) announced modifications to its contract with BARDA to speed up the development of key products including T2Biothreat, T2Resistance, and a comprehensive sepsis panel. The multi-year contract could be valued at up to $69.0 million. The changes allow for accelerated development of these vital panels designed to detect various pathogens and antibiotic resistance. The contract is part of a broader effort to enhance diagnostics and manage sepsis, significantly impacting patient outcomes by reducing diagnostic times and improving treatment options.
T2 Biosystems has announced a meta-analysis published in Expert Review of Medical Devices, demonstrating that its T2 Magnetic Resonance (T2MR) technology significantly reduces time to detection, species identification, and ICU and hospital stays for patients with bloodstream infections (BSIs). Key findings include a reduction of 81 hours in detection time and 77 hours in species identification compared to standard blood cultures. Patients receiving T2MR results were treated faster with targeted therapy, potentially lowering hospital costs by up to $25,000 per patient.
T2 Biosystems (NASDAQ:TTOO) will report its first quarter 2021 financial results after market close on May 6, 2021. A conference call will follow at 4:30 p.m. ET. T2 Biosystems specializes in the rapid detection of sepsis-causing pathogens, aiming to enhance patient care and reduce treatment costs. Their product lineup includes the T2Dx® Instrument and various diagnostic panels powered by proprietary T2 Magnetic Resonance technology. Interested parties can access the conference call via the company’s website or by phone.
T2 Biosystems (NASDAQ:TTOO) CEO John Sperzel has published a book detailing his personal battle with sepsis and a bloodstream infection. The book, titled Courage: Powerful Lessons in Leadership, Strength, and the Will to Succeed, aims to raise awareness of sepsis, which affects over 1.7 million Americans annually. The CDC reports sepsis costs the U.S. healthcare system more than $62 billion per year. Sperzel advocates for culture-independent rapid diagnostic tests to expedite treatment and potentially reduce mortality rates by 8% for each hour of delay.
T2 Biosystems (NASDAQ:TTOO) announced on March 26, 2021, the issuance of inducement awards to eighteen new employees, under its Inducement Award Plan. These awards include options to purchase 413,000 shares at an exercise price of $1.68, the closing price on March 25, 2021. The options vest over four years. T2 Biosystems specializes in rapid detection of sepsis-causing pathogens and aims to enhance patient care while reducing costs. The company continues to innovate with products like the T2Dx® Instrument and has a robust pipeline of future offerings.